PARP1 and breast carcinoma: The TGMO-based screen led us to select 4 drugs, 3 of which are FDA-approved for use in breast cancer, that is tamoxifen [30], the PI3Kα inhibitor alpelisib [50] and the PARP inhibitor talazoparib [110].